Home
Message from Chairman
Board of Directors
Company Overview
Company Values
Key Facts
Products
Export
Enquiry
MillatPharmaceuticals
MillatChemical
MillatFoods
MehfuzTrading
MAWInternational
DeshProcharoni
Piotab-30
 Key Product >>Piotab-30

Piotab-30
Pioglitazone INN Tablet

Presentation:
Piotab-15 : Each tablet contains Pioglitazone Hydrochloride INN equivalent to Pioglitazone 15 mg
Piotab-30 : Each tablet contains Pioglitazone Hydrochloride INN equivalent to Pioglitazone 30 mg.

Description:
Piotab is a member of the newest class of oral antidiabetic agents called thiazolidinediones which depend on the presence of insulin for its mechanism of action. Piotab decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. It also improves abnormality in lipid metabolism by activating PPAR-y receptor.

Indications:
Piotab is indicated as an adjunct to diet and exercise to improve glycemic control in patient with type- (diabetes (NIDDM). Piotab is indicated for Monotherapy and also indicated for use in combination with a sulfonylurea, Metformin or insulin when diet and exercise plus the single agent does not result in adequate glycemic control.

Dosage and Administration:
Piotab can be taken once daily without regard to meals. The managemant of Anti-diabetic therapy should be individualised.Piotab monotherapy in patients not adequately controlled with diet and exercise may be initiated at 15mg to 30mg daily. For palients who respond inadequately to the initial dose of Piotab, the dose can be increased up to 45mg once daily. For patients not responding adequately to monotherapy, combination therapy should be considered.


Side effects:
The overall incidence and types of adverse events reported in placebo controlled clinical trials of pioglitazone monotherapy at doses of 7.5 mg, 15 mg, 30mg or 45 mg once daily are shown below : Upper respiratory tract infections 13.2% headache 9.1% sinusitis 6.3% myalgia 5.4% tooth disorder 5.3 % & pharyngitis 5.1%.

Precautions:
Pioglitazone exerts its hypoglycemic effect only in the presence of insulin. Therefore it should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis. Pioglitazone should be used with caution in case of combination therapy, hepatic insufficiency and heart diseases.

Use in pregnancy and lactation:
Pregnancy: There are no adequate and well controlled studies in pregnant women, Pioglitazone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers: It is not known whether pioglitazone is secreted in human milk. Because many drugs are excreted in human milk. It should not be administered to a breast feeding women.

Contraindications:
Pioglitazone is contraindicated in patients with known hypersensitivity to this product or any of its components.

Over dosage:
In the event of over dosage, appropriate supportive treatment should be initiated according to patient's clinical signs and symptoms.

Commercial pack:
Piotab-15 : Each box contains 3 blister strips of 10 tablets.
Piotab-30 : Each box contains 2 blister strips of 10 tablets.